Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Using leucine to reverse muscle loss in cirrhosis

Official title: Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Run by The Cleveland Clinic · NCT03208868 · Data updated 2026-11-12

This study is testing if a special mixture of amino acids, including leucine, can help people with cirrhosis regain lost muscle and improve their strength.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment32 (estimated)
SponsorThe Cleveland Clinic
Academic / other
Locations1 site (Cleveland, Ohio)
StatusRecruiting
StartedAugust 5, 2013
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedAugust 21, 2026
Trial IDNCT03208868 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are cirrhotic patients with a Child's Pugh score of 5-9 who have abstained from alcohol and recreational drugs for at least six months.

Probably not a fit

Patients with a Child's score greater than 9, concurrent serious illnesses, or those on medications affecting muscle mass may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of a leucine enriched essential amino acid mixture to combat sarcopenia, a common complication in patients with cirrhosis. The researchers hypothesize that leucine can stimulate mTOR signaling, which may enhance protein synthesis and reduce muscle loss. By administering this amino acid mixture, the study aims to quantify changes in skeletal muscle mass in cirrhotic patients. The approach is based on preliminary findings suggesting that impaired mTOR signaling contributes to muscle loss in these patients.

Why it matters

Potential benefit: If successful, this treatment could significantly improve muscle mass and overall health in patients with cirrhosis.

How similar studies have gone: While the approach is based on preliminary studies, there is limited evidence from similar studies, making this a novel investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Cirrhotic patients:
* Cirrhosis diagnosed by liver biopsy and/or clinical, biochemical and imaging evidence of cirrhosis.
* Abstinence from alcohol and/or other recreational drugs for at least 6 months
* Child's Pugh score 5-9 (inclusive).

Exclusion

* Cirrhotic patients:
* Child's score \>9
* Pedal edema above the ankle
* Presence of concurrent illnesses (renal, cardiac, pulmonary, cerebrovascular, malignancy) or medication (anabolic steroids, corticosteroids) intake that affect skeletal muscle mass.
* Diabetes mellitus
* Active gastrointestinal bleeding
* Sepsis, encephalopathy
* Renal failure
* Hepatocellular carcinoma outside of Milan criteria
* Unwilling to sign informed consent or follow research procedures
* Does not meet inclusion criteria

Where it's running

  • Cleveland Clinic Foundation
    Cleveland, Ohio, United States
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.